Liquamar (phenprocoumon) is a small molecule pharmaceutical. Phenprocoumon was first approved as Liquamar on 1982-01-01. It is used to treat pulmonary embolism, thromboembolism, and venous thrombosis in the USA. The pharmaceutical is active against vitamin K epoxide reductase complex subunit 1.
|Indication||pulmonary embolism, thromboembolism, venous thrombosis|